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Transforming growth factor-b1 (TGF-b1) mRNA has low
basal translational efficiency in proximal tubule cells;
however, its translation is stimulated by profibrotic cytokines.
We studied the role of the multifunctional Y-box protein-1
(YB-1) in regulating proximal tubule cell TGF-b1 translation.
Using RNA-electrophoretic mobility shift assays and
ultraviolet crosslinking, we found two protein complexes
of 50 and 100 kDa, which bound to the TGF-b1 mRNA
50-untranslated region. Supershift studies using antibodies
to YB-1 showed that both sites contained YB-1 as did studies
with recombinant YB-1, which demonstrated that it was
sufficient to form both complexes. RNA competition
experiments confirmed YB-1 binding to the two predicted
binding sites; one with high affinity and the other with lower
affinity. Strong basal YB-1 association with TGF-b1 mRNA
was found in proximal tubule cells, which decreased
when platelet-derived growth factor was used to activate
TGF-b1 translation. In contrast, knockdown of proximal
tubule cell YB-1 expression abrogated TGF-b1 synthesis.
Our results suggest that TGF-b1 translation in proximal
tubule cells requires YB-1 binding to a high-affinity site in
the 50-untranslated region of its mRNA; however, binding
to a low-affinity site inhibits basal translation.
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The rate of progression of renal disease correlates closely with
the degree of interstitial fibrosis.1 Much of our work has
focused on the possible mechanisms of the pathogenesis of
interstitial fibrosis, and in particular the role of proximal
tubular epithelial cells. Recent studies have highlighted the
role of proximal tubular cells (PTCs) epithelial–mesenchymal
transition in genesis of renal interstitial fibrosis.2,3 Trans-
forming growth factor-b (TGF-b) is an important mediator
of the pathogenesis of numerous fibrotic diseases (reviewed
in Blobe et al.4) and is known to be an important stimulus
driving epithelial–mesenchymal transition.5 This has led us to
study the regulation of PTC TGF-b1 synthesis. We have
demonstrated that in PTC, TGF-b1 synthesis is indepen-
dently regulated at the levels of transcription and translation.
Exposure of PTC to elevated D-glucose concentrations
increases the generation of a poorly translated TGF-b1
transcript without any associated change in TGF-b1 protein
synthesis.6 Pretreatment of PTC with elevated glucose
concentrations followed by stimulation with platelet-derived
growth factor (PDGF) has synergistic effects on TGF-b1
synthesis.7 PDGF at low dose does not influence TGF-b1
transcription, but leads to alteration in TGF-b1 mRNA
stability and translation. In contrast, prolonged culture of
PTC under conditions of high glucose stimulates de novo
TGF-b1 synthesis, a process that involves a glucose-
dependent increase in TGF-b1 transcription, and delayed
stimulation of PDGF-a receptor signaling, which stimulates
TGF-b1 mRNA translation.8 Inhibition of PDGF receptor
activation with imatinib reduces tubulointerstitial TGF-b1
synthesis and ameliorates renal fibrosis in a mouse model of
diabetic nephropathy.9 Regulation of TGF-b1 translation is
also a key part of autoinduction of TGF-b1 synthesis in
PTC.10 Together, these results emphasize the potential
importance of translational regulation of TGF-b as a
therapeutic target in chronic kidney disease.
The 2.5 kb TGF-b1 transcript is inherently poorly
translated in cultured rat and human cells and in mouse
liver,11–14 and has unusually long, GC-rich 50 and 30
untranslated regions (UTR),15 features that are suggestive
of translational control.16 In contrast to the 30UTR of
TGF-b1, which is inherently stimulatory to translation,17 the
50UTR inhibits translation in vitro. Deletion analysis of the
50UTR using heterologous reporter gene constructs suggests
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that the region between nucleotides þ 11 and þ 147, termed
the ‘D region,’ is the key part of this sequence with respect
to inhibition of translation11 (schematically depicted in
Figure 1). This region is sufficient to inhibit translation
of a reporter gene 22-fold. Nucleotides þ 49 to þ 77 of the
D region are predicted to form a stem loop and bind a
previously unidentified cytosolic protein.12 In different
contexts, protein binding to this region has been associated
with both positive and negative effects on TGF-b1 transla-
tion.13,18 In this study, we have shown that the regulatory
Y-box binding protein-1 (YB-1) binds to this region of
TGF-b1 mRNA. YB-1 is reported to specifically associate with
mRNA as well as DNA sequences19 and profoundly alters
mRNA degradation as well as translation rates, for example, of
human preprorenin by associating with its mRNA 30UTR20
and granulocyte macrophage colony-stimulating factor in
allergic asthma.21 Here, we report that translational activation
of TGF-b1 is associated with alterations in the association
of YB-1 with the D region, while manipulation of YB-1
expression directly alters PTC TGF-b1 synthesis.
RESULTS
Detection of proteins that bind to the TGF-b1 50UTR in PTCs
The TGF-b1 50UTR is long (840 nucleotides) and GC-rich,
features suggesting translational regulation of gene expres-
sion.15 Within this region, stimulatory and inhibitory
elements have been identified, which are schematically
depicted in Figure 1a and b. The functionally relevant region
þ 11/þ 147 (depicted in Figure 1c) is predicted to undergo
conformational changes with formation of a stem loop
structure,12 which is highlighted by capital letters. For RNA
binding analysis, probes were used that include this predicted
stem loop structure, denoted ‘D probe,’ or that lack this
sequence element, denoted ‘Delta-D probe.’
Protein extracts from human kidney-2 (HK-2) cells were
analyzed for interaction with the major inhibitory region of
the TGF-b1 50UTR by electrophoretic mobility shift analysis
using radio-labeled RNA probes (RNA-EMSA). Two retarded
bands were seen with the D probe (Figure 2a). Probe
retardation occurred with the addition of 0.1 mg or more of
cell protein, but with only one band visible when lower
protein quantities were used (Figure 2c, lane 2), suggesting
that the two protein complexes had differing affinity for the
probe.
RNA-EMSAs were performed using radio-labeled Delta-D
probe (the D region with deleted stem loop, compare Figure
2b and c). These demonstrated the presence of a single
retarded band (Figure 2b), thus suggesting that there are two
protein binding sites within the D region, one within
nucleotides þ 49 to þ 77 and the other outside this region.
Formation of the retarded complexes was prevented by the
addition of an excess of unlabeled RNA of identical sequence
to the probe, suggesting that there was a limited pool of
protein that could interact with this region of the 50UTR
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Figure 1 | Human TGF b-1 transcript sequence. (a) Schematic diagram of TGF-b RNA transcript, illustrating the 50UTR, coding sequence,
and 30UTR. (b) Positions of the major inhibitory and stimulatory regions and of the putative stem loop structure. (c) Nucleotide sequence
of D region. The nucleotides in capital letters are predicted to form a stem loop and are deleted in the Delta-D probe. The underlined
nucleotides are the two YB-1 binding sites predicted from comparative sequence analysis. (d) Analysis of potential YB-1 binding sites within
the D region sequence. Homology to known YB-1 sites is indicated. Two potential binding sites were identified, starting at nucleotide
þ 21 and at nucleotide þ 68.
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(Figure 2c) and confirming the sequence specificity of this
interaction.
RNA-EMSAs were performed using protein from cells
sequentially treated with glucose and PDGF, stimuli pre-
viously shown to cause a sustained increase in TGF-b mRNA
translation.7 Loss of the more retarded band was seen with
the glucose and PDGF-treated cell extracts (Figure 2d),
suggesting that there are changes in protein association with
the D region when translation of TGF-b mRNA is activated.
Characterization of proteins binding to the D region in PTCs
To clarify the nature of the two retarded bands seen by RNA-
EMSA, we analyzed HK-2 cell protein binding to the D
region by ultraviolet (UV) crosslinking. Two separate protein
complexes were detected over a range of ionic strengths,
confirming that there were two different complexes that
could form around the D region with molecular weights
approximately 50 and 100 kDa (Figure 3a). Translational
regulation by YB-1 binding to areas of 50UTR secondary
structure22 together with our sequence analysis (Figure 1d)
suggested YB-1 as a likely component of these complexes. We
therefore performed UV crosslinking experiments in the
presence of polyclonal anti-YB-1 antibody. Addition of an
anti-YB-1 antibody interfered with the formation of the
probe–protein complexes (Figure 3b), whereas irrelevant
antibody had no effect (data not shown).
To confirm that YB-1 alone was capable of forming
complexes with the D probe, RNA-EMSAs were performed
using recombinant YB-1 protein. Two bands were seen on
RNA-EMSA using 0.3 mg recombinant purified YB-1 protein
per binding reaction and the D region probe (Figure 4a),
whereas EMSA using labeled Delta-D sequence showed a
single band (Figure 4a), reproducing the appearances found
with HK-2 cell protein.
We next assessed whether the amount of YB-1 that binds
to the D region varies with the ratio of protein to probe.
EMSA with serial dilutions of recombinant affinity-purified
YB-1, ranging from 0.003 to 3mg per binding reaction,
showed that the more retarded band requires a higher
concentration of YB-1 protein to form than the less retarded
band (Figure 4b), confirming that the amount of YB-1 binding
to the D region of the TGF-b1 50UTR varies with YB-1
availability, and reproducing the results obtained with cellular
proteins (Figure 2a and c).
Comparative analysis of the D region with known YB-1
binding sites
An analysis of the sequence of the D region suggested two
potential YB-1 binding sites on the basis of homology to
known binding sites for YB-1 within other RNA transcripts
(see Figure 1d). One site is located between nucleotides 21
and 27, and the other between nucleotides 68 and 84. The
second site is at the end of the putative stem loop structure
deleted in the Delta-D probe (Figure 1b and c). Synthetic
RNA with a sequence corresponding to the two putative
binding sites was used in competitor experiments with the
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Figure 2 | PTC protein binding to the D region. HK-2 cell protein
binding to D region examined by RNA-EMSA as described in Materials
and Methods. Bold arrow indicates the non-retarded free probe, thin
arrows indicate retarded bands. (a) RNA-EMSA using 3 mg HK-2 cell
protein and 300 pg D probe. (b) RNA-EMSA using 3 mg HK-2 cell
protein and 300 pg Delta-D probe (nucleotides 49–77 containing
putative stem loop deleted, see Figure 1). (c) RNA-EMSA using 0.3mg
cell protein, 300 pg D probe, and varying amounts of unlabeled D
probe competitor. Lane 2, no competitor; lane 3, 1.2 ng competitor
(4 ); lane 4, 12 ng competitor (40 ); lane 5, 120 ng competitor
(400 ). (d) RNA-EMSA using 3 mg protein from cells cultured in 5 mM
glucose for 96 h (lane 1) and 25 mM glucose for 96 h with PDGF-AA
25 ng ml1 for the last 48 h (lane 2).
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Figure 3 | Identification of proteins binding to the D region. HK-2
cell protein binding to D region examined by UV crosslinking as
described in Materials and Methods. Positions of 100 and 50 kDa size
standards are indicated. Bold arrow indicates the position of the
RNase-digested probe; thin arrows indicate the positions of protected
bands. (a) Effect of varying ionic strength on binding. KCl
concentration per mmol per l, lane 2: 100, lane 3: 150, lane 4: 200,
lane 5: 350. (b) Effect of antibody to YB-1 on binding. UV crosslinking
was performed using 6 mg HK-2 cell protein in the presence of 600 ng
polyclonal rabbit antibody to YB-1 as described in Materials and
Methods. Negative control (lanes 2–3), 1500 ng normal rabbit
immunoglobulin.
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D region probe to investigate the affinity of these binding
sites for YB-1 protein. Compared to the D region as a whole,
nucleotides 16–35 of the TGF-b1 50UTR had a relatively low
affinity for recombinant YB-1, showing significant compe-
titor activity only when present at 1000-fold molar excess
over probe (Figure 5a). In comparison, oligonucleotide 67–86
was an efficient competitor, inhibiting binding at 10-fold and
abrogating binding at 100-fold molar excess (Figure 5b). To
confirm the high affinity of nucleotides 67–86 of the TGF-b1
50UTR for YB-1, a further comparison was performed in a
competition assay with oligonucleotide 67–86 and the
unlabeled Delta-D probe. Oligonucleotide 67–86 was a highly
efficient competitor, whereas the Delta-D sequence showed
no detectable competitor activity at concentrations up to
400-fold molar excess (Figure 5c).
Activating PTC TGF-b1 translation reduces YB-1 binding to
TGF-b1 mRNA
We assessed whether TGF-b1 mRNA is constitutively
associated with YB-1 in PTCs and whether this association
is regulated by elevated glucose concentrations and PDGF-
AA. We have previously shown that sequential stimulation
with glucose and PDGF enhances TGF-b1 translation.7 Cells
were cultured in 5 or 17 mmol l1 glucose for 48 h and
subsequently PDGF-AA or vehicle was added. After 12 h
incubation, cell lysates were prepared. Total amount of RNA
did not vary (Figure 6a). The total number of TGF-b1
transcripts, assessed by reverse transcription-PCR, did not
differ in the four groups (Figure 6b). Cell lysates were
incubated with anti-YB-1 antibody, and the amount of
immunoprecipitated YB-1 was determined by western blot
analyses, yielding no major changes in YB-1 content in the
four groups (Figure 6c). Global mRNA association with YB-1
was reduced by PDGF (Figure 6d). Reverse transcription-
PCR of co-immunoprecipitated mRNA confirmed that
TGF-b mRNA was associated with YB-1 protein; this
association was reduced, but not abrogated, by sequential
stimulation with glucose and PDGF (Figure 6e). Quantitative
reverse transcription-PCR was also performed on immuno-
precipitated mRNA. YB-1-bound TGF-b mRNA was reduced
to 2.7% of the basal value by high glucose (17 mM) combined
with PDGF-A stimulation.
In view of the recent description by Evdokimova et al.23
of an Akt-dependent mechanism that governs association
of YB-1 with target mRNAs, we also tested whether the
amount of Akt-phosphorylated YB-1 changed in response to
elevated glucose concentration or PDGF-A, using an anti-
body generated against the phosphorylated YB-1 serine 102
residue;24 however, we did not detect changes in phosphory-
lation (data not shown).
Alterations in YB-1 expression change PTC TGF-b1 generation
We used knockdown of YB-1 with small interfering RNA
(siRNA) to assess the functional consequences of interaction
between the critical regulatory region of the TGF-b1 50UTR
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Figure 4 | YB-1 binding to the D region. Binding of recombinant
YB-1 protein to D and Delta-D probes by RNA-EMSA. (a) Lanes 1–2,
300 ng D probe; lanes 3–4, 300 ng Delta-D probe. Lanes 1 and 3
contain no cell protein; lanes 2 and 4 contain 0.3 mg recombinant
YB-1. Bold arrow indicates the position of the non-retarded probe,
thin arrows indicate the position of retarded bands. (b) Titration
of recombinant YB-1 quantity with 300 ng D probe RNA-EMSA.
Quantities of recombinant YB-1 are in lane 2, 3 ng; lane 3, 30 ng;
lane 4, 300 ng; and lane 5, 3 mg.
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Figure 5 | Evaluation of putative YB-1 binding sites. (a and b)
Affinity of putative YB-1 binding sites for YB-1 by competitor
RNA-EMSA using 0.3mg recombinant YB-1, 300 pg D probe, and
unlabeled competitor nucleotides 67–86 (a) or nucleotides 16–35
(b). Quantities of competitor in (a) and (b) are lane 2, 300 ng;
lane 3, 30 ng; lane 4, 3 ng; lane 5, no competitor. (c). Comparison of
Delta-D competitor with nucleotides 67–86. Quantities of competitor
are lane 2, no competitor; lane 3, 120 ng Delta-D; lane 4, 30 ng
Delta-D; lane 5, 120 ng nucleotide 67–86; lane 6, 30 ng nucleotides
67–86.
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and YB-1. HK-2 cells were transiently transfected with the
plasmid pSuperDuper (pSD)-YB-1, that generates siRNA
specific for YB-1, leading to decreases in endogenous YB-1
mRNA and protein levels of 80%, as assessed by quantitative
PCR and western blotting (Figure 7a). The control plasmid
pSD-control generates a scrambled siRNA sequence and had
no effect on YB-1 expression. pSD-YB-1 transfection resulted
in a significant decrease in TGF-b1 concentration in the cell
culture supernatant compared to both pSD-control transfec-
tion and untransfected cells (Figure 7b) (control untrans-
fected 339.8±6.5, control transfected 383.7±32.6, YB-1
siRNA transfected 231.7±12.7 pg per ml per 105 cells,
Po0.05 for YB-1 siRNA compared with either control).
Interestingly, TGF-b1 levels were consistently increased in
control transfected cell supernatant, possibly due to the
transfection procedure. Cellular protein extracts were tested
by RNA-EMSA for association with the D probe. Complex
formation with the D probe was markedly reduced with the
YB-1 siRNA protein extract (Figure 7c). TGF-b1 translation
was also assessed directly in cells expressing YB-1 siRNA,
by metabolic labeling of newly synthesized proteins with
3H-labeled amino acids and subsequent immunoprecipita-
tion of TGF-b1 from the cell culture supernatant. Using this
approach, de novo synthesis of TGF-b1 protein was not
detectable in cells following YB-1 knockdown, in contrast
with untransfected and control transfected cells (Figure 7d).
Control transfected cells demonstrated increased TGF-b1
synthesis compared to untransfected cells (Figure 7d,
compare lanes 1 and 2 with lanes 3 and 4). To confirm that
the inhibition of TGF-b1 translation by YB-1 siRNA was not
due to a general inhibition of protein synthesis, we measured
3H-labeled amino-acid incorporation into total cell protein
by scintillation counting (Figure 7e). This showed only 18%
reduction in 3H-labeled amino-acid incorporation in the
siRNA cells (control untransfected cells 4673±229, control
transfected cells 4546±56, YB-1 siRNA-expressing cells
3819±249 counts per min per 103 cells, Po0.05 for YB-1
siRNA cells vs untransfected and vs control transfected cells),
suggesting that the lack of detectable de novo TGF-b1
synthesis following YB-1 knockdown was not due to a
general abrogation of protein synthesis.
We also examined the effect of YB-1 overexpression on
TGF-b1 generation. HK-2 cells were transfected with various
doses of YB-1 overexpression vector (and control vector to
yield equal total amounts of plasmid DNA) before culture in
5 mM glucose for 96 h or 17 mM glucose for 96 h with PDGF-
AA at 25 ng ml1 for the final 48 h. Immunoblotting for YB-1
was performed to confirm the induced changes in YB-1
expression (Figure 8a). Total TGF-b in cell culture super-
natant was quantified by enzyme-linked immunosorbent
assay (Figure 8b). Glucose and PDGF caused a significant
increase in TGF-b, antagonized in a dose-dependent manner
by YB-1 overexpression.
DISCUSSION
The 2.5 kb TGF-b1 transcript is inherently poorly translated,
and translational activation of it occurs in response to
specific stimuli.7,8 A region of the 50UTR that maps to
nucleotides þ 11 to þ 147 (termed the D region) is
responsible for the strongly inhibitory effect of the TGF-b1
50UTR, whereas the other sections of the 50UTR as well as the
30UTR are neutral or stimulatory to translation.12,13,17 An
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unidentified cytosolic protein has previously been shown to
bind to the D region,12 and this interaction has been
associated with both positive and negative effects on TGF-b1
translation.13,18
We have used a combination of supershift experiments
and RNA-EMSA with recombinant protein to identify the
regulatory protein that binds to the TGF-b1 50UTR as YB-1
and have confirmed this interaction by using knockdown of
YB-1 with siRNA to abrogate protein binding. Eukaryotic
Y-box proteins possess multiple nucleic acid binding sites
that may interact with both DNA and RNA, controlling
transcription and translation of specific genes. They are
known to regulate mRNA stability in a sequence specific and
nonspecific manner.25–27 The human YB-1 is involved in the
post-transcriptional control of specific genes at multiple
levels, including RNA splicing of CD44,28 stability of
granulocyte macrophage colony-stimulating factor,21 inter-
leukin-2,22 and ferritin mRNA.29 YB-1 is an important
mediator of fibrosis in the kidney,30 as evidenced by its
regulation of expression of genes including collagen a-131
and gelatinase A.32–34 This study shows that it also regulates
the synthesis of the key profibrotic cytokine TGF-b1.
We identified two protein complexes that formed around
the D region of TGF-b1 mRNA, the more retarded complex
requiring a higher concentration of protein to form. Further
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Figure 8 | Effect of YB-1 overexpression on glucose/PDGF-AA-
stimulated TGF-b generation. Cells were transfected with various
doses of YB-1 overexpression vector (and control vector to yield
equal total amounts of plasmid DNA) before culture in 5 mM glucose
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final 48 h, as indicated. (a) Immunoblots of YB-1 expression and
GAPDH as loading control. (b) Supernatant total TGF-b detection
by enzyme-linked immunosorbent assay.
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experiments using recombinant YB-1 suggested that the
region þ 11 to þ 147 of the TGF-b1 50UTR binds one or two
YB-1 molecules in a concentration-dependent manner.
Although YB-1 protein may form multimers with preference
of dimer formation in the presence of ATP,35 our results are
most consistent with a two-site binding model for YB-1, as
complexes are independently formed at both sites and
differences in binding affinities are observed. Upon titration
of YB-1, two distinct complexes are formed only in the
presence of both recognition sites. Use of short synthetic
RNA competitors that are homologous to the two putative
binding sites confirmed that both compete for YB-1 binding
with the full-length probe. However, the nucleotide 16–35 site
is considerably less efficient as a competitor than the
nucleotide 67–86 site, suggesting that the nucleotide 67–86
site has a much higher affinity for YB-1. This is in keeping
with the competitor experiments showing that an excess of
Delta-D competitor, containing only the 16–35 binding site,
does not compete efficiently with the full-length probe for
protein binding, whereas an excess of full-length competitor,
containing both binding sites, compete efficiently.
By performing immunoprecipitation experiments, we
were able to detect the association of YB-1 with TGF-b1
transcripts in PTC. Subsequently, we demonstrated the
importance of this interaction in the regulation of TGF-b1
synthesis by showing that knockdown of YB-1 inhibits
de novo synthesis of TGF-b1 and causes a significant decrease
in basal TGF-b1 release. This suggests that YB-1 binding to
the D region is required for TGF-b1 translation. However,
our immunoprecipitation and EMSA experiments show rela-
tively high basal association between TGF-b1 mRNA and
YB-1 protein in PTCs and a reduction in association in
response to a combination of stimuli previously shown to
activate TGF-b1 translation in these cells (glucose and
PDGF). This suggests that an intermediate concentration of
cytoplasmic YB-1 is required for efficient TGF-b1 synthesis,
with higher or lower YB-1 concentrations being inhibitory
to translation. In keeping with this, overexpression of
YB-1 interfered with glucose and PDGF-stimulated TGF-b
generation (Figure 8).
YB-1 has previously been reported to have a biphasic
effect on translation, with low cytoplasmic concentrations of
YB-1 stimulating translation of specific mRNA species, but
higher concentrations being inhibitory secondary to displace-
ment of the eIF4G complex from the mRNA cap region.36
We speculate that at cytoplasmic concentrations of YB-1
sufficient to stimulate TGF-b translation, binding of YB-1
to the high-affinity site that we have identified melts the
secondary structure known to occur in this area and
allows unimpeded ribosome scanning, whereas at higher
YB-1 concentrations, binding to the low-affinity site
adjacent to the 50cap also occurs, interfering with translation
initiation and inhibiting TGF-b1 synthesis (Figure 9). This is
in keeping with the negative and positive effects on TGF-b1
translation that have been related to protein binding to the
D region.13,18
In summary, our study identifies YB-1 binding to the
TGF-b1 50UTR as a mechanism by which translation of
TGF-b1 is regulated in PTC and suggests that YB-1 may be a
desirable therapeutic target in chronic kidney disease.
MATERIALS AND METHODS
Cell culture and cell protein extraction
Experiments were performed using the human proximal tubular
epithelial cell line HK-2.37 Cell cultures and total cell protein
extracts were performed as described previously.38 In all aspects of
cell biology that we have studied previously, HK-2 cells respond in
an identical manner to primary cultures of human PTCs.7,8,18,39
They are therefore a good model from which general conclusions
can be drawn, in terms of proximal tubular cell biology.
Antibodies and recombinant protein production
Recombinant YB-1 was produced as described previously.40 Purity
of the expressed YB-1 fusion product was ascertained by analytic
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE). Polyclonal anti-YB-1 antibodies were peptide derived and
purchased from Antibodies-online (Aachen, Germany). Polyclonal
goat anti-nucleolin antibody (sc-9893) was purchased from Santa
Cruz Technology (CA, USA).
Gel retardation analysis and UV crosslinking
Probes for gel retardation and UV crosslinking were prepared by
in vitro transcription of linearized plasmids12 containing fragments
of the TGF-b1 50UTR (plasmids pGEM-D and pGEM-DD, a gift
from Dr SJ Kim, Laboratory of Carcinogenesis, NCI/NIH, Bethesda,
MD, USA). RNA probes internally labeled with 32P were generated
using the Riboprobe in vitro transcription kit (Promega, Madison,
WI, USA). The in vitro transcription mixture was gel isolated,
extracted twice with phenol–chloroform, and ethanol precipitated.12
Gel retardation analysis mixtures contained 300 pg radiolabeled
RNA and 0.03–6 mg recombinant or cell protein (as indicated in
the figures) in a total volume of 12 ml containing 20 mM HEPES
(4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid), 2 mM MgCl2,
5 mM dithiothreitol, 200 mM KCl, 200 mg ml1 bovine serum
albumin, 5% v/v glycerol, 5 mg ml1 heparin, and 100mg ml1 yeast
5′cap
5′UTR
ORF
YB-1
Ribosome
Translation 
intiation complex
Figure 9 | Proposed mechanism for regulation of TGF-b
translation by YB-1. (a) Cartoon of TGF-b 50UTR showing the
stem loop structure and the 50cap, the site of translation initiation.
(b) In the absence of YB-1 binding to its low-affinity site, the
translation initiation complex forms around the cap. (c) The
translation initiation complex recruits ribosomes, but in the absence
of YB-1 binding to its high-affinity site, ribosome scanning through
the 50UTR is impeded by the stem loop. (d) YB-1 binding to its
high-affinity site in the 50UTR melts RNA secondary structure,
allowing ribosome scanning, and increasing translation of TGF-b.
(e) At high concentrations, YB-1 binds to its low-affinity site,
displacing the translation initiation complex and preventing
ribosome recruitment.
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tRNA. Binding reaction at room temperature for 30 min was
followed by electrophoresis through 6% non-denaturing polyacryl-
amide gel in 45 mM Tris-borate/1 mM EDTA (pH 8.3). Gels were
dried and complexes were detected by autoradiography.
Unlabeled D region and Delta-D region RNA competitors were
synthesized in the same manner as the labeled probes. Competitor
20-mer RNA oligonucleotides were purchased from Dharmacon
(Lafayette, CO, USA) whose sequences spanned two putative YB-1
protein binding sites, nucleotides 16–35 (sequence GCAGCCAGACA
GCGAGGGCC) and nucleotides 67–86 (sequence GGGCACCCCCC
CCGGCTCTG).
Assay mixtures for UV crosslinking contained 600 ng probe and
0.03–6 mg recombinant or cell protein (as indicated in figures) in a
total volume of 5 ml containing 0.5 mg ml1 heparin, 20 mM HEPES,
2 mM MgCl2, 5 mM dithiothreitol, and KCl in the range 100–350 mM.
Subsequent experiments were performed using 100 mM KCl.
Following incubation at room temperature for 30 min, samples
were placed on ice and irradiated for 10 min using Stratalinker XL
1000 (Stratagene, La Jolla, CA, USA). A 25 ml portion of RNase A
(0.1 mg ml1) was added, and the samples were incubated at 37 1C
for 1 h before the addition of 15 ml non-denaturing loading buffer,
heated at 90 1C for 10 min, and electrophoresed through a 10%
SDS-polyacrylamide gel. After electrophoresis, the gel was dried and
autoradiographed.
Knockdown of endogenous YB-1 by siRNA
Cells were transfected with the empty vector pSD (OliogoEngine,
Seattle, WA, USA) or the pSuperDuper vector harboring a 63 bp
sequence that contains a tail-to-tail tandem repeat of 285–305 bp of
the human YB-1 coding sequence (accession no. J03827).30
Preliminary experiments demonstrated that transfection of this
construct caused reduction of YB-1 expression to approximately
20% of control values, at the levels of both mRNA and protein, and
had no effect on control (fibronectin) mRNA abundance (data not
shown).
Immunoprecipitation
Cells were cultured in 5 or 17 mM glucose for 48 h. Subsequently,
cells were stimulated with PDGF-A (at 25 ng ml1) or left
unstimulated for 12 h. Cells from the resulting four groups were
washed and snap-frozen at 80 1C and processed as described
previously.41 In brief, cell pellets were dissolved in lysis buffer
(50 mM Tris (pH 7.4), 150 mM NaCl, 1 mM EDTA, 10 mM NaF, 1
mM Na3, complete protease inhibitor mixture (Roche, Basel,
Switzerland), 1 mM dithiothreitol, 1 U ml1 of recombinant RNasin
(Promega), 0.1% Triton X-100, and 0.1% SDS) and passed through
a 29-gauge needle. The sheared lysates were cleared from cell debris
by centrifugation at 15 000 g for 10 min. A 12 mg portion of
anti-YB-1 antibody (Antibodies-online) was added for 2 h at 4 1C.
Protein G-agarose beads (Upstate Biotechnology, Lake Placid,
NY, USA) were added and incubation was continued overnight.
Pellets were washed five times with 1 ml of lysis buffer (without
detergent) and the last wash was split, with 60% dissolved in
TRI reagent (Sigma, Gillingham, Dorset, UK) and 40% dissolved in
SDS-PAGE loading buffer. RNA was isolated according to the
manufacturer’s recommendation. Reverse transcription reactions
were generated with oligo-dT primers (Promega), and PCR for
TGF-b1 was performed with forward primer 50CCTTTCCTGCTT
CTCATGGC30, reverse primer 50ACTTCCAGCCGAGGTCCTTG30,
at 95 1C for 5 min, 95 1C for 30 s, 51 1C for 30 s, 72 1C for 30 s, for 35
cycles.
Quantification of total TGF-b1
HK-2 cells were transfected with the vectors pSD-YB-1 and pSD-
control as described previously.7 In parallel experiments, cells were
left untransfected. After 16 h, the medium was removed and replaced
by fresh medium, and after 24 h, the medium was removed and total
TGF-b1 was quantified by sandwich enzyme-linked immunosorbent
assay (R&D Systems, Minneapolis, MN, USA) as described
previously.7
Metabolic labeling of de novo TGF-b1 synthesis
HK-2 cells were grown to 70% confluence in 25 cm2 tissue culture
flasks before transfection with the vectors pSD-YB-1 and pSD-
control using Fugene 6 (Roche) according to the manufacturer’s
instructions. After 48 h, the medium was removed and de novo
synthesis of TGF-b1 was assessed by metabolic labeling with 3H-
labeled amino acids and subsequent detection by immunoprecipita-
tion and SDS-PAGE/autoradiography as described previously.8
Quantification of total protein synthesis was performed in parallel
by scintillation counting of total cell protein extracts using a Tri-
Carb liquid scintillation counter (Packard, Berks, UK) and Ultima
Gold scintillation fluid (Packard) according to the manufacturer’s
instructions. Data are expressed as counts detected per min per 1000
cells.
Statistical analysis
Groups of data were compared by Student’s t-test, with no
assumption of equal variance, using the Microsoft Excel 2000
software package. Two-sided tests with a hypothesized mean
difference of zero and an a-level of 0.05 were performed.
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